NCT07216248View on ClinicalTrials.gov

Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

October 31, 2030

Study Completion Date

October 31, 2031

Conditions
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Interventions
DRUG

relugolix + ARPI

Step 1: Continuous treatment with relugolix + ARPI

DRUG

Intermittent- Relugolix or androgen deprivation therapy (ADT) + ARPI

Intermittent treatment with relugolix + ARPI.

DRUG

relugolix or androgen deprivation therapy (ADT) + ARPI

Step 2: Standard-of-care, continuous treatment with relugolix or androgen deprivation therapy (ADT) + ARPI.

DRUG

relugolix + ARPI.

Step 2: Intermittent treatment with relugolix + ARPI.

Trial Locations (1)

84112

Huntsman Cancer Institute at University of Utah, Salt Lake City

All Listed Sponsors
lead

University of Utah

OTHER